TNF and psoriatic arthritis: Available data so far suggest that csDMARDs (especially MTX) and anti-TNF-α comedication therapy, compared with anti-TNF-α monotherapy, are not superior in terms of treatment response but may be beneficial for biological treatment retention by reducing antidrug antibodies in axSpA and also in psoriatic arthritis (PsA) [56,57].